Inside the Science Journey to better understanding of LGMD: Q&A on the early findings of a new natural history study
Culture & Community Continuing a family legacy: Meet Sarepta colleague and Duchenne advocate Shawn Marlow
Patient Voices When time is muscle: One dad shares his story to advocate for Duchenne newborn screening
Advocates & Innovators Guardians of the last mile: Ensuring smooth delivery and a seamless patient experience
Advocates & Innovators A tale of two interns: Meet Kate & Katherine, rare disease advocates and members of Sarepta’s Patient Affairs team
Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Inside the Science Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Advocates & Innovators A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science Measurements used in clinical trials for Duchenne muscular dystrophy – an overview
Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community Giving thanks for our employees’ incredible dedication: Six employees explain why Sarepta is a Top Place to Work
Culture & Community How Sarepta infused its corporate brand with urgency and optimism on behalf of patients
